Bristol-Myers Squibb's flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy ...

Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star heart drug Camzyos faces new competition. A year ago, in the first quarter of 2025, BMS’ ...

In TUNER, Academy Award-winning director Daniel Roher’s first narrative feature, Leo Woodall stars as a gifted young piano tuner whose heightened sense of hearing draws the attention of criminals, who ...

Shimano has released its new PD-EH510 Hybrid SPD and Flat Pedal, which features an SPD mechanism on one side and a flat pedal on the other. The Japanese brand says the pedals are designed for ...

KUALA LUMPUR: BMS Holdings Bhd made a lacklustre debut on the ACE Market of Bursa Malaysia today, opening below its initial public offering (IPO) price of 22 sen per share. The Johor-based building ...

Bristol Myers Squibb is securing an opportunity to compete in the next generation of cell therapies through the $1.5 billion acquisition of Orbital Therapeutics, a startup with a lead program nearing ...

On the heels of the launch of an online direct-to-patient (DTP) program offering discounted Eliquis to certain U.S. patients, Bristol Myers Squibb is putting Sotyku at the center of its next DTP ...

When it comes to clipless pedals for road bikes, it's important that they be lightweight and easy to engage. Tourelly's Road Ceramic Ti pedals boast both features, thanks to a unique design that is ...

Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer, persuading Cristian Massacesi, M.D., to leave the Anglo-Swedish drugmaker and take responsibility of all its product ...

Add The Drive (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results Called ...

Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)–directed antibody‒drug conjugate (ADC), and pembrolizumab combination therapy: Initial results from an ongoing phase 1 study ...